Search Results for:
-
Oral Exam: Takeda's MM Bid Enters Phase III Combo Trial
The study includes a planned follow-up of up to five years," Dixie Esseltine, vice president of global clinical development for Takeda, told BioWorld Today, adding that MLN9708 is differentiated from competitors in three waysBy Randy Osborne | BioWorld Today | Friday, May 24, 2013 -
Jennerex Plucks $21.6M Private Placement; Is IPO Up Next?
The San Francisco-based company said proceeds, raised exclusively from existing shareholders and partner companies, will advance the clinical development of Pexa-Vec in HCC and in the follow-on indication of refractory colorectal cancerBy Marie Powers | BioWorld Today | Friday, May 24, 2013 -
Other News To Note
Galapagos NV, of Mechelen, Belgium, and AbbVie Inc., of Chicago, extended their clinical development collaboration on the oral JAK1 inhibitor GLPG0634 to include Crohn's disease...The pharma also will assume responsibility for funding and clinical development beyond Phase II and for completing regulatory and commercialization activitiesBioWorld International | Wednesday, May 22, 2013 -
Collaborations Between Biotech And Pharmaceutical Companies: April 1 - May 16, 2013
Ltd. (Seoul, South Korea) ND Licensing agreement for the anti-angiogenic peptide ALM201 for clinical development and marketing in South Korea Shin Poong will make undisclosed up-front and milestone payments, along with royalties 4/30/13 Ambrx Inc. (San Diego) Astellas Pharma Inc. (Tokyo) $300 Oncology-focused discovery and development collaboration in antibody drug conjugates Ambrx will receive $15M up front, and up to $285M in research, development, regulatory and sales-based milestones for anBioWorld Insight | Monday, May 20, 2013 -
Mirna Puts First MicroRNA Mimic into the Clinic
announced its first miRNA candidate for clinical development, RG-101, which also targets miR-122By Brian Orelli | BioWorld Insight | Monday, May 20, 2013 -
As Markets Fancy Biotech, PTC Therapeutics Joins IPO Queue
In its filing, the company said it plans to use proceeds from the IPO to fund the clinical development of lead candidate ataluren (formerly PTC124) in Duchenne's muscular dystrophy caused by nonsense mutations (nmDMD) and cystic fibrosis caused by nonsense mutations (nmCF), to seek marketing approval of ataluren in the indications in the U.SBy Marie Powers | BioWorld Today | Monday, May 20, 2013 -
Other News To Note
Galapagos NV, of Mechelen, Belgium, and AbbVie Inc., of Chicago, extended their clinical development collaboration on the oral JAK1 inhibitor GLPG0634 to include Crohn's disease...The pharma also will assume responsibility for funding and clinical development beyond Phase II and for completing regulatory and commercialization activitiesBioWorld Today | Monday, May 20, 2013 -
Oncos Targets Solid Tumors With Oncolytic Virus Approach
These 290 patients served as a base of clinical experience prior to kicking off our clinical development," Wuite told BioWorld TodayBy Marie Powers | BioWorld Today | Monday, May 20, 2013 -
RuiYi, Genor Blaze Trail in China with JV for Rheumatoid Arthritis
Genor BioPharma has more than 100 employees with 10 products in the pipeline, three at the IND or clinical-development stageBy Dave Silver | BioWorld Today | Friday, May 17, 2013 -
Pharma: Other News To Note
Merck Serono SA, of Rockland, Mass., a division of Merck KGaA, of Darmstadt, Germany, and Quintiles Inc., of Research Triangle Park, N.C., signed a new, five-year clinical development agreementBioWorld Today | Thursday, May 16, 2013 -
Astellas Axes OSI, Perseid Units, Cuts Jobs in Japan
In April 2014, Astellas said clinical development, quality assurance, regulatory affairs and pharmacovigilance functions – all currently located in Itabashi-ku, Tokyo – will be "relocated and consolidated" closer to the company's headquarters in Nihonbashi, Chuo-ku, TokyoBy Marie Powers | BioWorld Today | Wednesday, May 15, 2013 -
Beyond Kalbitor: Dyax Adds $30M for HAE Prophylactic
is more than doubling its cash position with a $30 million registered direct offering, with proceeds to fund R&D activities, namely clinical development of DX-2930, a drug slated to start clinical development for prophylactic use in hereditary angioedema (HAEBy Jennifer Boggs | BioWorld Today | Tuesday, May 14, 2013 -
Diagnostics Rapidly Evolving, Ideal Companions in Drug R&D
Moving Quickly While most drugs languish in clinical trials for upwards of a decade, Zelboraf and Xalkori were able to move quickly, largely due to the fact that both were paired with companion diagnostics very early in their clinical development, allowing them to find the right patient population, establish efficacy and present a convincing case to regulators. (See BioWorld Insight, Sept. 6, 2011.) "Early development of these tests also potentially enables clinical trials to be smaller and moreBy Peter Winter | BioWorld Insight | Monday, May 13, 2013 -
Array Expanding Capabilities, Runs First Phase III Trial
A partnership signed with Clovis Oncology Inc., of Boulder, Colo., last year, for example, calls for Clovis to be fully responsible for all aspects of preclinical and clinical development and commercialization of compounds discovered by ArrayBy Brian Orelli | BioWorld Insight | Monday, May 13, 2013 -
Isis Peers Beyond Kynamro, Seeks $171M for Pipeline
clinical development plan and financial terms relating to ISIS-TTRRx to reflect an accelerated development plan for that antisense drug...Isis has 28 candidates in preclinical and clinical development across a wide variety of indications, with nine scheduled to report data in the next 12 monthsBy Marie Powers | BioWorld Today | Friday, May 10, 2013 -
Blood Protein Reverses Heart Aging in Old Mice
In other words, if the protein is effective, clinical development might be more rapid than in cases where a drug candidate has to be identified to recapitulate an effectBy Anette Breindl | BioWorld Today | Friday, May 10, 2013 -
Other News To Note
CytRx said it will focus on clinical development of aldoxorubicin and expansion of its oncology pipeline, based on its linker platform technology...Nimbus will control and conduct research up to achievement of drug candidate status, at which point Shire will have an exclusive option to acquire the program and assume clinical development and future commercialization activitiesBioWorld Today | Thursday, May 9, 2013 -
AiCuris Wins Breakthrough Alliance Annual Deal Award
Menarini will be responsible for manufacture and clinical development of each product, with OBT providing proprietary cancer targets, antibody generation and drug conjugation technologiesBy Catherine Shaffer | BioWorld International | Wednesday, May 8, 2013 -
Bench Press: BioWorld Looks at Translational Medicine
The mTOR kinase is a key regulator of growth, and it is targeted by hundreds of agents now in preclinical and clinical development...Such inhibitors are in clinical development, but like most targeted therapies, work only for a time until tumors mutate their way around themBioWorld Today | Monday, May 6, 2013 -
Unexpected Toxicity has Lessons for Making Bispecific Antibodies
In terms of further clinical development of the antibodies, one question is – as always – how well the effects in mice predict those in peopleBy Anette Breindl | BioWorld Insight | Monday, May 6, 2013
Category
Current Filters
- xclinical development
Related Keywords
Categories
- x BioWorld Today (3600)
- x BioWorld International (1071)
- x BioWorld Insight (388)
- x Bio Perspectives (111)
- x State of the Industry Report (78)
- x BioWorld Snapshots (32)
- x BioWorld Genomics Review (29)
- x Executive Compensation Report (5)
- x Biotech Innovations (3)
- x RNAi Report (2)
- x Market-Leading Biotech Drugs (2)
- x Top 25 Drug Report (1)
- x Recorded (1)
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.